GSK Receives FDA Approval for Expanded Indication for Fluarix Quadrivalent (Influenza Vaccine) for Persons 6 Months and Older

Philadelphia, PA, January 11, 2018 -- GSK [LSE/NYSE: GSK] announced today it has received approval from the US Food and Drug Administration ’s (FDA) Center for Biologics Evaluation and Research expanding the indication for Fluarix Quadrivalent...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news